Morning, Marco. The big one this week is oncology, not hospital medicine — the FDA approved the first drug that actually hits the genetic driver of pancreatic cancer, and it roughly doubled second-line survival. That changes a conversation you have more often than you'd like. Also: a GLP-1 signal in dialysis patients, the season's fourth named storm finally showing up, and the debate over whether an AI can hold a medical license, which is closer to your floor than it sounds. Coffee, then sleep.
A · Top Stories
FDA · Oncology
FDA approves Rasonque for metastatic pancreatic cancer — median survival roughly doubles in the second line
On Wednesday the FDA approved Rasonque (daraxonrasib), Revolution Medicines' once-daily oral multi-RAS inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma. It is the first therapy to target the genetic driver of the disease rather than work around it. In the registrational data, second-line patients had a median overall survival of 13.2 months versus 6.7 months on standard chemotherapy. The approval landed about six and a half months ahead of the user-fee deadline, and more than 2,000 patients have already received the drug through an expanded access program that opened in May. RAS was considered undruggable for four decades; roughly 90% of pancreatic adenocarcinomas carry a KRAS mutation.
Why it matters to you: two things, both practical. First, the prognosis script changes. When you're the admitting physician at 2 a.m. for an elderly patient with known metastatic pancreatic cancer and a bowel obstruction or a biliary stent occlusion, the framing you've used for years — months, comfort-focused, probably no second act — is no longer automatically right, and the palliative care and goals-of-care conversation you tee up for the day team should not foreclose an oncology option that now exists. Second, this is an oral agent taken every day at home, which means it will start showing up in med recs. Expect the usual oral-oncolytic problems: patients who hold it during an admission and nobody restarts it, and patients who keep taking it through an AKI or a sepsis workup when the oncologist would have held it.
Action: ask your pharmacy whether daraxonrasib is on formulary yet and, more importantly, whether there is a standing rule for who decides to hold or continue an oral oncolytic on an unplanned medical admission. That gap is where these drugs cause trouble.
FDA announcement · STAT (Aug 26) · NBC News
GLP-1s · Nephrology
GLP-1s linked to lower inflammation and better anemia markers in hemodialysis patients
Reported Thursday: a retrospective real-world cohort out of the Renal Research Institute in New York, led by Suman Lama, matched 2,468 patients starting a GLP-1 receptor agonist (semaglutide, tirzepatide, dulaglutide, liraglutide or exenatide) against 2,468 patients who didn't, all on uninterrupted in-center hemodialysis for the 12 months after initiation. The GLP-1 group showed improvement in inflammatory and anemia biomarkers, with the authors framing it as a possible benefit in managing inflammation and inflammation-mediated anemia in kidney failure. Published in Kidney Medicine. It's observational and matched, not randomized — hypothesis-generating, not practice-changing.
Why it matters to you: less for what it proves than for where it points. Yesterday's item was that Medicare's GLP-1 Bridge program has already pushed roughly 200,000 prescriptions through two pharmacy chains, about half to GLP-1-naive patients. Now the evidence base is expanding into a dialysis population that was largely excluded from the original trials. You will increasingly admit ESRD patients on a GLP-1, and the inpatient questions are unchanged and unglamorous: last dose date before any procedure, gastric emptying and aspiration risk, and whether early-titration nausea and poor intake are driving the interdialytic weight and blood-pressure numbers everyone is arguing about on rounds.
Action: worth a two-minute mention to your nephrology colleagues — if they're already prescribing into this population, the anemia-marker signal is something they'll want to see before a rep brings it to them.
Medscape (Aug 27)
Weather · SWFL
Tropical Storm Dolly forms — the fourth named storm, arriving at what should be peak season
The National Hurricane Center named Tropical Storm Dolly Thursday night in the central Atlantic, about 1,315 miles east of the Leeward Islands, with 40 mph sustained winds — barely over the threshold. It's moving quickly west and is forecast to weaken back to a tropical wave before reaching the Leewards this weekend, though it may bring rain there. This is only the season's fourth named storm as August ends, a strikingly quiet count that forecasters attribute to a deepening El Niño in the Pacific.
Why it matters to you: nothing to do tonight — no Florida threat from this system. The reason it's here is the calendar. September 10 is the climatological peak, and a quiet August is exactly the setup where a hospital's surge and staffing plans go stale because nobody has had to open the binder. As the nocturnist you are the person on site when a storm-related activation happens overnight, and the shifts that matter are the ones where the evacuation of a coastal SNF or a dialysis-unit closure lands on your admissions at 11 p.m.
Action: before you sleep, one line to your group lead: does the nocturnist know the current storm-activation call tree and where the ride-out roster stands for September? Cheaper to ask in a quiet week.
CBS News · Fox Weather · NHC